Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXLNASDAQ:KYMRNASDAQ:MTSRNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$9.56+2.8%$8.48$3.78▼$14.44$793.96M0.681.18 million shs1.21 million shsKYMRKymera Therapeutics$47.14+1.8%$35.90$19.45▼$53.27$3.01B2.07610,825 shs570,077 shsMTSRMetsera$29.31+1.1%$26.16$12.30▼$37.99$3.05BN/A1.03 million shs440,990 shsSRRKScholar Rock$33.41+0.4%$31.80$6.76▼$46.98$3.16B0.281.29 million shs1.43 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+2.80%+7.17%+26.96%+2.14%+127.08%KYMRKymera Therapeutics+1.84%+1.70%+59.85%+55.12%+49.89%MTSRMetsera+1.07%+15.48%+7.36%+4.27%+2,930,999,900.00%SRRKScholar Rock+0.39%+7.26%+11.37%+3.89%+297.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.3447 of 5 stars3.70.00.04.70.60.80.6KYMRKymera Therapeutics3.502 of 5 stars4.53.00.00.03.71.70.0MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/ASRRKScholar Rock4.4548 of 5 stars3.62.00.04.43.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.33Buy$44.00360.25% UpsideKYMRKymera Therapeutics 3.00Buy$59.8226.91% UpsideMTSRMetsera 3.00Buy$55.0087.65% UpsideSRRKScholar Rock 3.14Buy$42.6727.71% UpsideCurrent Analyst Ratings BreakdownLatest AVXL, SRRK, MTSR, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$65.006/18/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.006/10/2025MTSRMetseraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $62.006/3/2025KYMRKymera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.006/3/2025KYMRKymera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.006/3/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$38.00 ➝ $60.006/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$49.00 ➝ $79.006/3/2025SRRKScholar RockLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/2/2025KYMRKymera TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$51.005/20/2025KYMRKymera TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.005/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AKYMRKymera Therapeutics$47.07M65.22N/AN/A$12.90 per share3.65MTSRMetseraN/AN/AN/AN/A($2.46) per shareN/ASRRKScholar Rock$33.19M95.58N/AN/A$3.94 per share8.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-40.93%-36.38%8/5/2025 (Estimated)KYMRKymera Therapeutics-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/ASRRKScholar Rock-$246.29M-$2.53N/AN/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)Latest AVXL, SRRK, MTSR, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million3/26/2025N/AMTSRMetseraN/A-$3.52N/A-$3.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A6.746.74KYMRKymera TherapeuticsN/A8.498.49MTSRMetseraN/A6.556.55SRRKScholar Rock0.1610.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%KYMRKymera TherapeuticsN/AMTSRMetseraN/ASRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.00%KYMRKymera Therapeutics16.01%MTSRMetseraN/ASRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.37 million75.98 millionOptionableKYMRKymera Therapeutics17065.12 million54.69 millionOptionableMTSRMetsera81105.06 millionN/AN/ASRRKScholar Rock14094.95 million82.32 millionOptionableAVXL, SRRK, MTSR, and KYMR HeadlinesRecent News About These CompaniesScholar Rock Holding Corp. (SRRK) Stock Price Today - WSJJune 24 at 8:47 PM | wsj.comScholar Rock Holding Corp News (SRRK) - Investing.comJune 24 at 8:47 PM | investing.comScholar Rock CEO on its drug that could preserve muscle in weight-loss drug usersJune 24 at 7:14 PM | youtube.comScholar Rock: EMBRAZE Results Drive The Stock HigherJune 23 at 9:40 PM | seekingalpha.comScholar Rock (NASDAQ:SRRK) Trading Down 5.7% - Time to Sell?June 22 at 4:21 AM | americanbankingnews.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from BrokeragesJune 21, 2025 | americanbankingnews.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from AnalystsJune 21, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Shares Down 5.7% - Should You Sell?June 20, 2025 | marketbeat.comScholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug TrialJune 19, 2025 | insidermonkey.comScholar Rock data show promise for muscle-preserving combo with ZepboundJune 19, 2025 | thepharmaletter.comScholar Rock (NASDAQ:SRRK) Given Outperform Rating at WedbushJune 19, 2025 | americanbankingnews.comScholar Rock (NASDAQ:SRRK) Receives Outperform Rating from WedbushJune 18, 2025 | marketbeat.comScholar Rock says its drug preserved lean mass in patients taking ZepoundJune 18, 2025 | statnews.comScholar Rock Jumps on Weight Loss Data for Zepbound/Repurposed Antibody ComboJune 18, 2025 | biospace.comScholar Rock's SMA drug helps weight loss patients on Zepbound retain muscle in phase 2 trialJune 18, 2025 | fiercebiotech.comScholar Rock stock soars after drug shows promise in preserving lean mass during weight lossJune 18, 2025 | au.investing.comScholar Rock lead asset causes higher quality weight loss with Lilly’s obesity drugJune 18, 2025 | msn.comScholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial ResultsJune 18, 2025 | msn.comScholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight LossJune 18, 2025 | msn.comWhy Scholar Rock Shares Are Soaring TodayJune 18, 2025 | fool.comScholar Rock (NASDAQ:SRRK) Shares Gap Up - What's Next?June 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksAVXL, SRRK, MTSR, and KYMR Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$9.56 +0.26 (+2.80%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$9.75 +0.19 (+1.99%) As of 08:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Kymera Therapeutics NASDAQ:KYMR$47.14 +0.85 (+1.84%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$44.94 -2.21 (-4.68%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Metsera NASDAQ:MTSR$29.31 +0.31 (+1.07%) As of 06/24/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Scholar Rock NASDAQ:SRRK$33.41 +0.13 (+0.39%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$34.40 +1.00 (+2.98%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Insiders Chase Income and Stability in American Tower—Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
